Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500967PMID: 30000026
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1326244-10-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of tildrakizumab during breastfeeding. Because tildrakizumab is a large protein molecule with a molecular weight of 147,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Some professional guidelines state that the drug is acceptable to use during breastfeeding.[3] Until more data become available, tildrakizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[4]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Psoriasis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Phototherapy, Tretinoin
References
- 1.
- Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
- 2.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
- 3.
- Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update. Br J Dermatol 2020;183:628-37. [PubMed: 32189327]
- 4.
- Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]
Substance Identification
Substance Name
Tildrakizumab
CAS Registry Number
1326244-10-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Secukinumab.[Drugs and Lactation Database (...]Review Secukinumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Mogamulizumab.[Drugs and Lactation Database (...]Review Mogamulizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Pembrolizumab.[Drugs and Lactation Database (...]Review Pembrolizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Basiliximab.[Drugs and Lactation Database (...]Review Basiliximab.. Drugs and Lactation Database (LactMed®). 2006
- Review Mepolizumab.[Drugs and Lactation Database (...]Review Mepolizumab.. Drugs and Lactation Database (LactMed®). 2006
- Tildrakizumab - Drugs and Lactation Database (LactMed®)Tildrakizumab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...